For Jeff Albers, the decision to step down as the CEO of Blueprint Medicines after eight years is a “natural evolution” for the growing biotech company that allows other executives to step up into more senior roles.
In a leadership transition announced Wednesday, Albers will exit his CEO post in April but will remain with Blueprint as executive chairman. Current Chief Operating Officer Kate Haviland was promoted to CEO. Christina Rossi, the company’s chief commercial officer, will move into Haviland’s former COO role.
“When we look at the state of the company, we are in an incredibly strong spot right now,” said Albers, making this the right time to transition the CEO role to Haviland. “We always try to operate in a team model, because frankly, good companies evolve over time by building better for the longer term.”
About the Author Reprints
Create a display name to comment
This name will appear with your comment
